[18F]-FDG PET/MR 评估结直肠癌的诊断效能:一项系统评价与 Meta 分析
本系统评价与 Meta 分析纳入 18 项研究共 1534 例患者,计算 [18F]-FDG PET/MR 检测结直肠癌的诊断效能。患者水平汇总敏感度为 0.94(95%CI:0.89-0.97)、特异度为 0.89(95%CI:0.84-0.93);病灶水平汇总敏感度为 0.93(95%CI:0.82-0.98)、特异度为 0.95(95%CI:0.90-0.98)。作者认为该 modality 在结直肠癌分期与再分期中可发挥重要作用,尤其在排除病灶/转移方面,且治疗后诊断效能未受影响。
要点
- 患者水平汇总敏感度 0.94(95%CI:0.89-0.97)、特异度 0.89(95%CI:0.84-0.93)。
- 病灶水平汇总敏感度 0.93(95%CI:0.82-0.98)、特异度 0.95(95%CI:0.90-0.98)。
- 亚组中 M 分期敏感度最高 0.97(95%CI:0.86-0.99),N 分期敏感度最低 0.81(95%CI:0.65-0.91)。
核心结论
- 本 Meta 分析显示 [18F]-FDG PET/MR 检测结直肠癌病灶/转移总体诊断效能较高,可在结直肠癌分期与再分期的多个临床场景中发挥重要作用。
- 作者指出该 modality 的主要优势之一是排除结直肠癌病灶/转移的存在。
- 作者报告治疗后背景下总体诊断效能未受影响。
研究设计与样本
- 本系统评价与 Meta 分析遵循 PRISMA-DTA 指南设计,检索截至 2021 年 12 月 31 日发表的原创文章。
- 纳入标准为:评估 [18F]-FDG PET/MR 作为结直肠癌诊断方法;以组织病理学为参考标准,无病理时以临床/影像复合随访为参考标准;提供足够的原始数据供 Meta 分析。
- 共纳入 18 项研究、1534 例患者,在患者水平和病灶水平计算汇总诊断效能。
- 亚组分析包括 TNM 分期、T 分期、N 分期、M 分期、肝转移,以及直肠癌患者水平和直肠癌病灶水平亚组。
- 采用分层方法汇总效能,双变量模型确定汇总点,使用 STATA 16 进行分析。
主要发现
- 结直肠癌病灶检测(肿瘤、淋巴结和转移)患者水平汇总敏感度为 0.94(95%CI:0.89-0.97),病灶水平为 0.93(95%CI:0.82-0.98)。
- 患者水平汇总特异度为 0.89(95%CI:0.84-0.93),病灶水平为 0.95(95%CI:0.90-0.98)。
- 亚组中 M 分期敏感度最高,为 0.97(95%CI:0.86-0.99)。
- 直肠癌病灶水平亚组特异度最高,为 0.99(95%CI:0.84-1.00)。
- N 分期敏感度最低,为 0.81(95%CI:0.65-0.91);T 分期特异度最低,为 0.79(95%CI:0.52-0.93)。
关键数值与推荐
- 患者水平汇总敏感度 0.94(95%CI:0.89-0.97),汇总特异度 0.89(95%CI:0.84-0.93)。
- 病灶水平汇总敏感度 0.93(95%CI:0.82-0.98),汇总特异度 0.95(95%CI:0.90-0.98)。
- M 分期亚组敏感度 0.97(95%CI:0.86-0.99)。
- 直肠癌病灶水平亚组特异度 0.99(95%CI:0.84-1.00)。
- N 分期亚组敏感度 0.81(95%CI:0.65-0.91),T 分期亚组特异度 0.79(95%CI:0.52-0.93)。
临床怎么用
- 作者认为 [18F]-FDG PET/MR 可在结直肠癌分期与再分期的多个临床场景中发挥重要作用。
- 作者指出该 modality 的主要优势之一是排除结直肠癌病灶/转移的存在。
- 作者报告治疗后背景下总体诊断效能未受影响。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To calculate the diagnostic performance of [18F]-FDG PET/MR in colorectal cancer (CRC). METHODS: This study was designed following the PRISMA-DTA guidelines. To be included, published original articles (until December 31, 2021) that met the following criteria were considered eligible: (1) evaluated [18F]-FDG PET/MR as the diagnostic method to detect CRC; (2) compared [18F]-FDG PET/MR with histopathology as the reference standard, or clinical/imaging composite follow-up when pathology was not available; (3) provided adequate crude data for meta-analysis. The diagnostic pooled measurements were calculated at patient and lesion levels. Regarding sub-group analysis, diagnostic measurements were calculated in "TNM staging," "T staging," "N staging," "M staging," and "liver metastasis" sub-groups. Additionally, we calculated the pooled performances in "rectal cancer: patient-level" and "rectal cancer: lesion-level" sub-groups. A hierarchical method was used to pool the performances. The bivariate model was conducted to find the summary points. Analyses were performed using STATA 16. RESULTS: A total of 1534 patients from 18 studies were entered. The pooled sensitivities in CRC lesion detection (tumor, lymph nodes, and metastases) were 0.94 (95%CI: 0.89-0.97) and 0.93 (95%CI: 0.82-0.98) at patient-level and lesion-level, respectively. The pooled specificities were 0.89 (95%CI: 0.84-0.93) and 0.95 (95%CI: 0.90-0.98) at patient-level and lesion-level, respectively. In sub-groups, the highest sensitivity (0.97, 95%CI: 0.86-0.99) and specificity (0.99, 95%CI: 0.84-1.00) were calculated for "M staging" and "rectal cancer: lesion-level," respectively. The lowest sensitivity (0.81, 95%CI: 0.65-0.91) and specificity (0.79, 95%CI: 0.52-0.93) were calculated for "N staging" and "T staging," respectively. CONCLUSION: This meta-analysis showed an overall high diagnostic performance for [18F]-FDG PET/MR in detecting CRC lesions/metastases. Thus, this modality can play a significant role in several clinical scenarios in CRC staging and restaging. Specifically, one of the main strengths of this modality is ruling out the existence of CRC lesions/metastases. Finally, the overall diagnostic performance was not found to be affected in the post-treatment setting.
引用
- Mirshahvalad SA, Hinzpeter R, Kohan A, et al. Diagnostic performance of [18F]-FDG PET/MR in evaluating colorectal cancer: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2022. PMID: 35705874. doi:10.1007/s00259-022-05871-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。